Júlia Carolina Ferreira

Mrs. Júlia Carolina Ferreira

Mestrado em Int. Est. e Func. na Reabilitação, Universidade de Marília, Marília, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RLROSA ANDREA NOGUEIRA LAISO
ROSA ANDREA NOGUEIRA LAISO
Júlia Carolina FerreiraJúlia Carolina Ferreira
Júlia Carolina Ferreira
RRRose Eli Grassi Rici
Rose Eli Grassi Rici
Laertty Garcia de Sousa CabralLaertty Garcia de Sousa Cabral
Laertty Garcia de Sousa Cabral
DMDurvanei Maria
Durvanei Maria
Cancer stands out as a major global public health concern and a significant impediment to increasing life expectancy worldwide. Natural bioactives derived from plants are renowned for their efficacy in treating various types of cancer. Andrographis paniculata (Burm.f.) is a well-known plant traditionally employed in diverse medical systems across the globe. The 2-AEH2P monophosphoester, a molecule intricately involved in phospholipid turnover, demonstrates antiproliferative effects across a broad spectrum of cancer types. This study aims to assess the antitumor, antiproliferative, and pharmacological effects of andrographolide at different concentrations, both individually and in conjunction with 2-aminoethyl dihydrogen phosphate. The cytotoxicity of the treatments was evaluated using the colorimetric MTT method, cell cycle phases, mitochondrial electrical potential, and markers expression via flow cytometry, while the pharmacological effects were assessed using SynergyFinder software 3.0. Treatments with A. paniculata, isolated at concentrations of 10%, 30%, and 50% of andrographolide, induced cell death in tumor cells, resulting in a reduction in mitochondrial electrical potential and alterations in cell cycle phases, particularly a decrease in the population of MDA MB-231 cells in the G0/G1 phase. The combination treatments exhibited significant cytotoxicity toward tumor cells, with minimal toxicity observed in normal fibroblast cells FN1. This led to a reduction in mitochondrial electrical potential and cell cycle arrest in the S phase for MDA MB-231 cells. Across all concentrations, the combined treatments demonstrated a synergistic pharmacological effect, underscoring the efficacy of the association. There was a change in the markers involved in cell death, such as p53, caspase 3, Bcl-2, and cytochrome c, suggesting the induction of regulated cell death. Markers associated with progression and proliferation, such as cyclin D1 and p21, corroborate the findings for cytotoxicity and cell cycle arrest.

9 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KPKarina Torres Pomini
Karina Torres Pomini
Júlia Carolina FerreiraJúlia Carolina Ferreira
Júlia Carolina Ferreira
LSLaira Mireli Dias da Silva
Laira Mireli Dias da Silva
PTPaulo Gabriel Friedrich Totti
Paulo Gabriel Friedrich Totti
MAMonique Gonçalves Alves
Monique Gonçalves Alves
RRRose Eli Grassi Rici
Rose Eli Grassi Rici
Background/Objectives: Although the nanocomposite of poly(L-lactic acid) with graphene oxide (PLLA-GO) shows promise for tissue engineering, its specific bioactive interactions with diverse cell lineages during early tissue regeneration remain unclear. This study comprehensively investigated the in vitro multifaceted biocompatibility of PLLA-GO using human fibroblasts (FN1 cells), murine mesenchymal stem cells (mBMSCs), and human umbilical vein endothelial cells (HUVECs). Methods: Morphological analyses were performed using optical and scanning electron microscopy, while proliferation dynamics were assessed via CFSE staining. Cell cycle progression was evaluated using flow cytometry, mitochondrial activity was examined through TMRE staining, and inflammatory cytokine profiling was performed via Cytometric Bead Array (CBA). Results: PLLA-GO exhibited primary biocompatibility across all evaluated cell lines, characterized by efficient adhesion and proliferation. However, significant cell-type-dependent modulations were observed. The FN1 cells exhibited proliferative adaptation but induced accelerated scaffold degradation, as evidenced by a substantial increase in cellular debris (5.93% control vs. 34.38% PLLA-GO; p = 0.03). mBMSCs showed a transient initial proliferative response and a significant 21.66% increase in TNF-α production (179.67 pg/mL vs. 147.68 pg/mL in control; p = 0.03). HUVECs demonstrated heightened mitochondrial sensitivity, exhibiting a 32.19% reduction in mitochondrial electrical potential (97.07% control vs. 65.82% PLLA-GO; p ≤ 0.05), alongside reductions in pro-inflammatory cytokines TNF-α (8.73%) and IL-6 (12.47%). Conclusions: The PLLA-GO processing method is crucial for its properties and subsequent cellular interactions. Therefore, rigorous and specific preclinical evaluations—considering both cellular contexts and fabrication—are indispensable to ensure the safety and therapeutic potential of PLLA-GO in tissue engineering and regenerative medicine.

5 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KPKarina Torres Pomini
Karina Torres Pomini
Júlia Carolina FerreiraJúlia Carolina Ferreira
Júlia Carolina Ferreira
LSLaira Mireli Dias da Silva
Laira Mireli Dias da Silva
PTPaulo Gabriel Friedrich Totti
Paulo Gabriel Friedrich Totti
MAMonique Gonçalves Alves
Monique Gonçalves Alves
RRRose Eli Grassi Rici
Rose Eli Grassi Rici
Background/Objectives: While the nanocomposite of poly(L-lactic acid) with graphene oxide (PLLA-GO) shows promise for tissue engineering, its specific bioactive interactions with diverse cell lineages during early tissue regeneration remain unclear.. This study comprehensively investigated PLLA-GO's multifaceted in vitro biocompatibility using human fibroblasts (FN1), murine mesenchymal stem cells (mBMSCs), and human umbilical vein endothelial cells (HUVECs). Methods: We assessed morphological characteristics via optical and scanning electron microscopy, proliferation using CFSE, cell cycle progression with flow cytometry, mitochondrial potential via TMRE, and inflammatory cytokine profiles through Cytometric Bead Array (CBA). Results: PLLA-GO demonstrated primary biocompatibility across all cell lines, characterized by efficient adhesion and proliferation. However, significant cell-type-dependent modulations were observed. FN1 cells exhibited proliferative adaptation but induced accelerated scaffold degradation, evidenced by a substantial increase in cellular debris (5.93% control vs. 34.38% PLLA-GO; p=0.03). mBMSCs showed a transient initial proliferative response and a significant 21.66% increase in TNF-α production (179.67 pg/mL vs. 147.68 pg/mL in control; p=0.03). Notably, HUVECs displayed pronounced mitochondrial sensitivity, with a 32.19% reduction in mitochondrial electrical potential (97.07% control vs. 65.82% PLLA-GO; p≤0.05), alongside reductions in pro-inflammatory cytokines TNF-α (8.73%) and IL-6 (12.47%). Conclusions: The PLLA-GO processing method is crucial for its properties and subsequent cellular interactions. Therefore, rigorous and specific preclinical evaluations, considering both cellular contexts and fabrication, are indispensable to ensure the safety and therapeutic potential of PLLA-GO in tissue engineering and regenerative medicine.

10 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MHMariana Hirata
Mariana Hirata
RGRogerio Padovan Gonçalves
Rogerio Padovan Gonçalves
MSMaria Eduarda Teixeira Pereira Cândido da Silva
Maria Eduarda Teixeira Pereira Cândido da Silva
GFGeovanna de Castro Feitosa
Geovanna de Castro Feitosa
CSCaio Spilla
Caio Spilla
KPKarina Torres Pomini
Karina Torres Pomini
Background/Objectives: Breast cancer is a biologically complex malignancy whose high prevalence and therapeutic resistance represent a continuous challenge for global health. The Tumor Microenvironment (TME) is a crucial component in disease progression, and the Extracellular Matrix (ECM), particularly its 3D collagen architecture, is recognized for mediating interactions that influence invasion, metastasis, and pharmacological response. This review aims to critically synthesize recent evidence to elucidate the multifaceted role of collagen in the progression and modulation of therapeutic response in breast adenocarcinoma. Methods: A comprehensive literature review was conducted, analyzing studies addressing specific collagen subtypes, ECM stiffening (fibrosis), biomechanical signaling, and their impact on drug transport kinetics and immunomodulatory effects. Results: The results demonstrate that structural alterations of collagen not only orchestrate a pro-tumoral microenvironment, fostering aggressive phenotypes and immune evasion, but also create a physical barrier that compromises drug delivery efficiency and promotes metastatic dissemination. The synthesis of the data reinforces collagen as a potent prognostic biomarker and a promising therapeutic target for overcoming stroma-mediated resistance. Conclusions: Targeting the collagen-rich stroma and its 3D network is a critical frontier for therapeutic innovation. Developing adjuvant strategies to modulate the ECM has the potential to enhance clinical outcomes and optimize the distribution of antineoplastic agents, especially in patients with high degrees of tumor fibrosis.

6 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MHMariana Hirata
Mariana Hirata
RGRogerio Padovan Gonçalves
Rogerio Padovan Gonçalves
MSMaria Eduarda Teixeira Pereira Cândido da Silva
Maria Eduarda Teixeira Pereira Cândido da Silva
GFGeovanna de Castro Feitosa
Geovanna de Castro Feitosa
CSCaio Spilla
Caio Spilla
KPKarina Torres Pomini
Karina Torres Pomini
Background/Objectives: Breast cancer is a biologically complex malignancy whose high prevalence and therapeutic resistance represent a continuous challenge for global health. The Tumor Microenvironment (TME) is a crucial component in disease progression, and the Extracellular Matrix (ECM), particularly its 3D collagen architecture, is recognized for mediating interactions that influence invasion, metastasis, and pharmacological response. This review aims to critically synthesize recent evidence to elucidate the multifaceted role of collagen in the progression and modulation of therapeutic response in breast adenocarcinoma. Methods: A comprehensive literature review was conducted, analyzing studies addressing specific collagen subtypes, ECM stiffening (fibrosis), biomechanical signaling, and its impact on drug transport kinetics and immunomodulatory effects. Results: The results demonstrate that structural alterations of collagen not only orchestrate a pro-tumoral microenvironment, fostering aggressive phenotypes and immune evasion, but also create a physical barrier that compromises drug delivery efficiency and promotes metastatic dissemination. The synthesis of the data reinforces collagen as a potent prognostic biomarker and a promising therapeutic target for overcoming stroma-mediated resistance. Conclusions: Targeting the collagen-rich stroma and its 3D network is a critical frontier for therapeutic innovation. Developing adjuvant strategies to modulate the ECM has the potential to enhance clinical outcomes and optimize the distribution of antineoplastic agents, especially in patients with high degrees of tumor fibrosis.